Seoul, South-Korea (October 23, 2015)

Invited by the State Secretary for Education, Research and Innovation, Swiss Medendi is participating in the 2nd Swiss-Korean Life Science Symposium from October 21 to 23, 2015. Shahar Tsabari is presenting Swiss Medendi within the MedTech Start-up Pitching on Friday, October 23, in the JW Marriott Dongdaemoon in Seoul, Korea.

About the Swiss-Korean Life Science Symposium

The Swiss-Korean Life Science Symposium is a forum for scientists, medical doctors, industry leaders and entrepreneurs from both Switzerland and Korea focused on medical technology, life science and global health. The event is co-organised by the Embassy of Switzerland in Korea and the Korea Health Industry Development Institute (KHIDI). Main sponsors are the Korean Ministry of Health and Welfare (MOHW) and the Swiss State Secretariat for Education, Research and Innovation (SERI) as well as Novartis, Roche, Roche Diagnostics and MedTech Innovation Partners (MTIP). For more information on the Swiss-Korean Life Science Symposium, please visit

About Swiss Medendi

Swiss Medendi SA is a Switzerland based start-up company offering a proprietary, cost-efficient and easy-to-use intravenous (IV) infusion device, the HC100, for safe administration of chemotherapeutics and other vesicant and irritant drugs – protecting patients’ veins and vessels from vesicant damages, and preventing patients from injuries and complications associated today with ports and catheters. Employing the HC100 will help hospitals to manage costs and enable doctors to focus more on their patients’ needs.